



INFORMATION DISCLOSURE STATEMENT PTO-1449		ATTY. DOCKET NO. 39766-0205		SERIAL NO. 10/719,310		
		APPLICANT: Paul G. Brunetta et al.				
		FILING DATE: 11/21/2003		GROUP: 1644		
U.S. PATENT DOCUMENTS						
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE
FOREIGN PATENT DOCUMENTS						
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES
						<input type="checkbox"/>
						<input type="checkbox"/>
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
	Adams et al., "Humanization of a Recombinant Monoclonal Antibody to Produce a Therapeutic HER Dimerization Inhibitor, Pertuzumab" Cancer Immunotherapy, Springer-Verlag, BE, vol. 55, no. 6, pp. 717-727 (2006) XP019333247 ISSN: 1432-0851.					
	Agus et al., "Targeting Ligand-Activated ErbB2 Signaling Inhibits Breast and Prostate Tumor Growth" Cancer Cell, vol. 2, pp. 127-137 (2002) XP002988666.					
	Franklin et al., "Insights into ErbB Signaling from the Structure of the ErbB2-pertuzumab Complex" Cancer Cell, XX, US, vol. 5, no. 4, pp. 317-328 (2004) XP002372929 ISSN: 1535-6108.					
	Jackson et al., "Blockade of Epidermal Growth Factor-or Heregulin-Dependent ErbB2 Activation with the Anti-ErbB2 Monoclonal Antibody 2C4 has Divergent Downstream Signaling and Growth Effects" Cancer Research, vol. 64, no. 7, pp. 2601-2609 (2004) XP002453734 ISSN: 0008-5472.					
	Yarden et al., "Untangling the Erbb Singalling Network" Nature Reviews Molecular Cell Biology, MacMillan Magazines, London, GB, vol. 2, no. 2, pp. 127-137 (2001) XP009072338.					
EXAMINER		DATE CONSIDERED				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.